دورية أكاديمية

The Heart failure and Optimal Outcomes from Pharmacy Study (HOOPS): rationale, design, and baseline characteristics.

التفاصيل البيبلوغرافية
العنوان: The Heart failure and Optimal Outcomes from Pharmacy Study (HOOPS): rationale, design, and baseline characteristics.
المؤلفون: Lowrie, Richard, Mair, Frances S., Greenlaw, Nicola, Forsyth, Paul, McConnachie, Alex, Richardson, Janice, Khan, Nina, Morrison, Deborah, Messow, Claudia-Martina, Rae, Brian, McMurray, John J.V.
المصدر: European Journal of Heart Failure; Aug2011, Vol. 13 Issue 8, p917-924, 8p, 1 Diagram, 4 Charts
مصطلحات موضوعية: HEART failure treatment, PRIMARY care, HEALTH outcome assessment, PHARMACY, RANDOMIZED controlled trials, ACE inhibitors, ANGIOTENSIN-receptor blockers, CLINICAL trials
مستخلص: Aims The effect on mortality and morbidity of pharmacist-led intervention to optimize pharmacological therapy in patients with systolic heart failure (HF) has not been tested in a large-scale, long-term, clinical trial. Methods We describe the rationale and design of a UK, primary care-based, prospective cluster-randomized controlled trial of a pharmacist-led intervention in HF and report baseline characteristics of the patients randomized. Eighty-seven practices (1092 patients) were assigned to the intervention arm and 87 practices (1077 patients) to usual care. The average age of patients at baseline was 71 years, 70% were male, 86% were treated with an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker and 62% with a beta-blocker. Data for the primary outcome of death from any cause or hospitalization for HF will be available up to 31 December 2010, giving a mean follow-up of 5 years. More than 750 patients would have experienced the primary outcome during this period. The first secondary outcome is death from any cause or hospitalization for a cardiovascular reason. Deaths and hospitalizations are being identified using the Scottish National Health Service electronic patient record-linkage system (hence the delay between the end of follow-up and database lock). Conclusion This trial is powered to provide a robust evaluation of the effect of pharmacist-led treatment optimization in patients with systolic HF in primary care. [ABSTRACT FROM AUTHOR]
Copyright of European Journal of Heart Failure is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
قاعدة البيانات: Complementary Index
الوصف
تدمد:13889842
DOI:10.1093/eurjhf/hfr083